Revvity to Present at J.P. Morgan Healthcare Conference
Get Alerts RVTY Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.2%
EPS Growth %: +2.5%
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA.
President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities.
To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and will be available for at least 30 days.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217854213/en/
Investor Relations:
Steve Willoughby
[email protected]
Media Relations:
Chet Murray
(781) 462-5126
[email protected]
Source: Revvity
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Rock-It Company Expands to Abu Dhabi, Strengthening the Capital’s Position as a Global Hub for Luxury, Culture, and Major Events
- PureHealth Research Peptide Supplements Expand with New Morikol® Tripeptide Formula for Faster Cellular Absorption
- Venture Insights Opens Its Diagnostic to Saudi Founders at No Cost and Has a Named Expert Sign Every Playbook
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share